opdivo

Drug Access Update Nivolumab (Opdivo)

Bristol Myers Squibb (BMS) has just announced that they will extend the “Melody” compassionate access program for those patients with metastatic melanoma to allow patients access where there is limited or no private insurance coverage until April 1st, 2019. While we are patiently waiting for final price negotiations to conclude and then potential provincial listing and coverage, this extension will help a significant number of metastatic patients. Thank you to BMS, Annette Cyr and everyone who worked hard to allow Canadians equal access to this life saving drug treatment.

opdivo

SHARE THIS POST

You must be logged in to post a comment.
Next Post
Considerations for Adjuvant Therapy
Previous Post
Cherry & Winter Root Cobbler

MELANOMA SUPPORT

The Melanoma Network of Canada has a number of free services for patients, caregivers and healthcare professionals.

SUBSCRIBE

Sign up to receive the latest news from Melanoma Network of Canada

DONATE

Help Make a Difference to the Lives of Canadians Changed by Melanoma

Menu